DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
focused on the treatment of diabetes and its complications, today announced it
will be presenting a poster titled "Safety, Tolerability, Pharmacokinetics and
Pharmacodynamics of Recombinant Human Tissue Kallikrein-1 (DM199) in Healthy
Volunteers and Patients with Type 2 Diabetes Mellitus" at the American Diabetes
Association's (ADA) 74th Scientific Sessions, being held on June 13-17 in San
Francisco, California. 


The poster has been assigned the presentation number 0977-P in category 01-D
Clinical Therapeutics/New Technology - Non-Insulin Injectables. The poster is
scheduled to be presented on Saturday, June 14th, 2014 from 11:30-1:30 pm.


About DiaMedica 

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage product, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
John Savage
Chief Financial Officer
763-208-6434
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024